Objectives: Point of care testing (POCT) offers the possibility of near bedside patient testing with a reduction of the turn-around time of analysis. The aim of our study was to determine the analytical performances and usability of a recently developed POCT device for the measurement of tests related to liver function. We evaluated the performance of a liver tests panel performed on the LINX EVO® POCT device.
Design And Methods: The imprecision was determined with the Bio-Rad Liquichek Unassayed Chemistry Control. Method comparison was performed with a Cobas® 8000 analyzer. Samples from twenty healthy volunteers were used to verify the reference intervals. Furthermore, practicality was assessed by the healthcare staff handling the POCT device through a dedicated questionnaire.
Results: The imprecision observed was matching the criteria for the in-lab assay with only one exception, globulin, with an observed imprecision of 6.3 % and a criteria of 5.7 %. With the exception of total and direct bilirubin, the POCT method showed good agreement with the in-lab methods. The verification of reference intervals showed that more than 90 % of the healthy volunteer values were included into the reference interval claimed by the manufacturer except for glucose and globulin. The POCT practicality questionnaire was satisfying overall for users.
Conclusions: Our study showed very good analytical performances overall for the liver test panel performed on the LINX EVO® POCT instrument.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10847987 | PMC |
| http://dx.doi.org/10.1016/j.plabm.2024.e00367 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultrasensitive and selective impedance paper-based analytical device through Dual-C imprinted sensor for determination of carcinoembryonic antigen and C-reactive protein.
Mikrochim Acta
January 2025
Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Ubon Ratchathani University, Ubon Ratchathani, 34190, Thailand.
Carcinoembryonic antigen (CEA) and C-reactive protein (CRP) are biomacromolecules known as cancer and inflammatory markers. Thus, they play a crucial role in early cancer diagnosis, post-treatment recurrence detection, and tumor risk assessment. This paper describes the development of an ultrasensitive and selective imprinted paper-based analytical device (PAD) as impedance sensor for determination of CEA and CRP in serum samples for point-of-care testing (POCT).
View Article and Find Full Text PDFA machine-learning-integrated portable electrochemiluminescence sensing platform for the visualization and high-throughput immunoassays.
Talanta
January 2025
College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen, Guangdong 518060, PR China. Electronic address:
Electrochemiluminescence (ECL)-based point-of-care testing (POCT) has the potential to facilitate the rapid identification of diseases, offering advantages such as high sensitivity, strong selectivity, and minimal background interference. However, as the throughput of these devices increases, the issues of increased energy consumption and cross-contamination of samples remain. In this study, a high-throughput ECL biosensor platform with the assistance of machine learning algorithms is developed by combining a microcolumn array electrode, a microelectrochemical workstation, and a smartphone with custom software.
View Article and Find Full Text PDFBudget impact analyses of hemoglobin A1c and lipid panel point-of-care testing with Afinion™ 2 in Canada and Italy.
J Comp Eff Res
January 2025
Abbott Rapid Diagnostics, 110 Viale Thomas Alva Edison, Sesto San Giovanni, MI, Italy, 2009.
Screening and monitoring of diabetes or dyslipidemia frequently involves a multi-step process requiring patients to obtain test requisitions from their primary care physician (PCP), followed by a laboratory visit and re-consultation. Point-of-care testing (POCT) for hemoglobin A (HbA) and lipid panel can streamline the patient care pathway. This study assessed the budget impact of introducing Afinion™ 2 POCT (Abbott Rapid Diagnostics) from the Canadian and Italian societal perspectives.
View Article and Find Full Text PDFScreening for sickle cell disease by point-of-care tests in Italy: pilot study on 1000 at risk children.
Eur J Pediatr
January 2025
Department of Woman, Child and General and Specialized Surgery, University of Campania 'Luigi Vanvitelli', Via Luigi De Crecchio 4, Naples, Italy.
Unlabelled: Sickle cell disease (SCD) is a global health problem causing premature deaths and preventable severe chronic complications. A priority goal to improve outcomes both in the short and long term is the screening for early diagnosis and access to specialized care. In Italy, as in other countries, no systematic national screening program is available.
View Article and Find Full Text PDFLift-CM: An integrated lift-heater centrifugal microfluidic platform for point-of-care pathogen nucleic acid detection using isothermal amplification and CRISPR/Cas12a.
Biosens Bioelectron
January 2025
Anhui Institute of Optics and Fine Mechanics, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, PR China. Electronic address:
Pathogen nucleic acid detection technology based on isothermal amplification and CRISPR/Cas12a system offers advantages in terms of high sensitivity, high specificity, and rapidity. However, this method has not been widely applied because of its shortcomings in utilizing conventional instruments, which cannot satisfy the requirements for Point of Care Testing (POCT), such as integration, convenience, and miniaturization. In this study, we developed an integrated lift-heater centrifugal microfluidic platform (Lift-CM) to automate the processes of isothermal amplification and CRISPR/Cas12a detection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!